Coverage
Filings
Zealand Pharma on Thursday reported a significant surge in revenue and profit for the first nine months of 2025, driven by its recent partnership with Roche, while also announcing it has paused development of its experimental obesity drug, dapiglutide.
Zealand Pharma's revenue and profit soared in the first half of 2025, a direct result of a major partnership with Roche to develop its new weight-loss drug candidate, petrelintide.
Zealand Pharma on Wednesday reported positive results from a mid-stage study of its experimental obesity drug, dapiglutide, showing an average body weight reduction of 11.6% over 28 weeks.
| 15 Nov 2011 |
| Notice of Interim Report for the first nine months of 2011 and conference call | 11 Nov 2011 |
| Zealand Pharma wins Management Team of the Year at the 2011 Scrip Awards | 4 Nov 2011 |
| Zealand Pharma announces that a European regulatory application has been submitted for Lyxumia® (lixisenatide) by its partner Sanofi, as a novel once-daily GLP-1 agonist for Type-2 diabetes | 3 Nov 2011 |
| Zealand Pharma nominates Market Maker on NASDAQ OMX Copenhagen | 1 Nov 2011 |
| Zealand Pharma to host a Capital Markets Day in New York | 19 Oct 2011 |